Rhino Health has had a successful and eventful year in 2022. The company has made significant progress towards its goal of accelerating the development and deployment of artificial intelligence (AI) in healthcare, by connecting developers to decentralized medical data.
The Ongoing Rhino Health Platform Evolution: Our platform has expanded to support the full range of AI development, from data discovery and ingestion to pre-processing, analytics, and AI/ML, all without moving data or losing control over it. We are now multi-cloud, and support on-premises installations as well as all major cloud providers. In addition, we’ve expanded our channel partnership with NVIDIA and will soon be available on the AWS marketplace.
Expanding the Rhino Network: In 2022, multiple healthcare organizations (HCOs) joined the Rhino Network, including some of the most prominent academic medical centers in the United States and Israel. The network now includes HCOs from the US, Israel, UK, Brazil, and APAC.
The Rhino Health Platform in Action: The abundance of leading AI developers on the network has driven an exponential increase in activity, including the formation of the Federated Learning For Medicine (FL4M) consortium, the National Cancer Institute's Early Detection Research Network, and many other active development projects over a broad spectrum of use-cases.
Large Enterprises Unlock Value By Using The Platform: We signed up several enterprise customers, such as the American College of Radiology, a strategic partnership with NTT DATA and biopharma companies such as AstraZeneca (as part of the BeyondBio SCALE Accelerator).
Looking ahead to 2023, Rhino Health expects to see continued rapid growth, fueled by a combination of the need for more broad and diverse data, together with mounting concerns over data privacy, security and ownership.
The Regulatory Environment Continues To Evolve: Health systems are required to provide unprecedented access and interoperability, in line with the Final Rule of the 21st Century Cures Act, NIH guidance on sharing research datasets and additional regulations. This happens at the same time as the industry awaits further instructions regarding Software-as-a-Medical-Device (SaMD) regulation. Federation shines as a way to meet these new demands and changes while controlling risk.
The Market Attitude Shifts Toward Federation: Cybersecurity risks, public perception of data privacy and ownership and the onus of maintaining compliance will lead the US to a more EU-like approach to data privacy and a preference towards more "arms length" approaches to accessing real-world data, especially when used by the biopharma industry and tech companies. Rhino Health's decentralized approach to data processing and computation is well-suited to this developing environment.
Commodification of “Simple” Data & “Simple” Use-cases: We also expect that "simple" data will become commoditized, with the value lying in the "secret sauce" of data processing and modeling as well as in more niche data modalities, multi-modal data and longitudinal outcomes, all pushing the envelope on providing access from multiple sources and thus further driving the need in the Rhino Health Platform.
It’s a rapidly evolving world, and we believe that we can help shape it in an ethical, transparent and ‘democratized’ way, with our approach to liberating medical data. We can’t wait to start this year, and looking forward to working with our customers on accelerating healthcare AI.
All the best,
Dr. Ittai Dayan MD, MPH
Co-founder & CEO, Rhino Health
Image credit to DALL-E-2, created on 01/05/2023